Jaffer A. Ajani

122.4k citations

939 papers · 45.2k indexed · 17 hit papers · h-index 101

Impact in

Gastroenterology top 0.01%
- Gastrointestinal Tumor Research and Treatment
Pulmonary and Respiratory Medicine top 0.01%
- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies

Papers in

Gastroenterology 141
- Gastrointestinal Tumor Research and Treatment 140
Pulmonary and Respiratory Medicine 628
- Gastric Cancer Management and Outcomes 544
- Metastasis and carcinoma case studies 124

Co-authors: Stephen G. Swisher Leonard L. Gunderson Wayne L. Hofstetter Shumei Song Daniel G. Haller James C. Yao Norman Estes Jack A. Roth
Journals: Journal of Clinical Oncology (175 papers)Cancer (67 papers)International Journal of Radiation Oncology*Biology*Physics (48 papers)Annals of Oncology (47 papers)Annals of Surgical Oncology (28 papers)
Partner nations: United States Japan China

In The Last Decade

Jaffer A. Ajani

915 papers receiving 44.3k citations

Hit Papers

15 papers align trajectories log scale

Advances in diagnosis and management of cancer of the esophagus 2024 · 62 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 BMJ
2023 The Lancet
2023 The Lancet Oncology
2021 Cell Communication and Signaling
2020 Cell Research
2017 Annals of Surgical Oncology
2017 Nature Reviews Disease Primers
2017 The Lancet Oncology
2014 The Lancet Oncology
2013 Journal of Clinical Oncology
2012 Journal of Clinical Oncology
2012 Journal of Clinical Oncology
2010 Journal of Clinical Oncology
2008 JAMA
2006 Journal of Clinical Oncology
2001 New England Journal of Medicine
1998 New England Journal of Medicine

Peers

Countries citing papers authored by Jaffer A. Ajani

Since Specialization

Citations

This map shows the geographic impact of Jaffer A. Ajani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaffer A. Ajani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaffer A. Ajani more than expected).

Fields of papers citing papers by Jaffer A. Ajani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaffer A. Ajani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaffer A. Ajani. The network helps show where Jaffer A. Ajani may publish in the future.

Co-authors

The 25 scholars most cited alongside Jaffer A. Ajani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jaffer A. Ajani Line = papers co-authored together Jaffer A. Ajani links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648 Annals of Oncology ·И В Макляев, Ian Chau, Jaffer A. Ajani, Yuko Kitagawa, Subin Jeong, Lucjan Wyrwicz, Mirzayev Orifjon Nurmuhammedovich, Takashi Ogata, Jesús Blanco Hidalga, Sara Gallardo Trillo, Kathiravan Purmal, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Mariela Blum Murphy, E. K. Maslovsky, Nan Hu, Yasuhiro Matsumura, Koji Kato, Y. Doki	2024	0
2	Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study Cancers ·Matheus Sewastjanow‐Silva, Lianchun Xiao, Graciela M. Nogueras‐González, Xuemei Wang, Wayne L. Hofstetter, Stephen G. Swisher, Reza J. Mehran, Boris Sepesi, Manoop S. Bhutani, Brian Weston, Emmanuel Coronel, Rebecca Waters, Jane E. Rogers, Y Jiménez-Martínez, L. R. Lyons, Norelle R. Reilly, James C. Yao, Jaffer A. Ajani, Mariela Blum Murphy	2024	1
3	Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data ESMO Open ·Jaffer A. Ajani, Lai K. Leung, Steve Kanters, Parul Singh, Murat Kurt, Martina Kerscher, Alain Cagnati, Howard S. Frıedman, Prakash Navaratnam, Gregory Reardon	2024	2
4	Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy Annals of Surgical Oncology ·Yuki Hirata, Annamaria Agnes, Jeannelyn S. Estrella, Mariela Blum Murphy, Prajnan Das, Bruce D. Minsky, Jaffer A. Ajani, Brian D. Badgwell, Paul Mansfield, Naruhiko Ikoma	2023	5
5	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer Molecular Cancer Therapeutics ·Yuping Yin, Weizhen Liu, Qian Shen, Peng Zhang, Lulu Wang, Sivani Andreia dos Santos, Hang Li, Xianxiong Ma, Xiangyu Zeng, Jae‐Ho Cheong, Shumei Song, Jaffer A. Ajani, Gordon B. Mills, Kaixiong Tao, Guang Peng	2019	16
6	PPARδ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression Molecular Cancer Research ·Shumei Song, Zhenning Wang, Yuan Li, Lang Ma, Jiankang Jin, Ailing W. Scott, Yan Xu, Jeannelyn S. Estrella, Yongxi Song, Bin Liu, Randy L. Johnson, Jaffer A. Ajani	2019	23
7	A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma Molecular Cancer Therapeutics ·Shumei Song, Min Xie, Ailing W. Scott, Jiankang Jin, Lang Ma, Xiaochuan Dong, Heath D. Skinner, Randy L. Johnson, Sheng Ding, Jaffer A. Ajani	2017	141
8	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer Molecular Cancer Therapeutics ·Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A. Ajani, Jiří Tomášek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S. Melemed, Ling Gao, David Ferry, Charles S. Fuchs	2017	34
9	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer Clinical Cancer Research ·Yung‐Jue Bang, Y. Choi, Yeul Hong Kim, Jin Won Kim, Maria Di Bartolomeo, Jaffer A. Ajani, Kensei Yamaguchi, Ágnes Balogh, Teresa Sánchez, Markus Moehler	2017	113
10	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer Clinical Cancer Research ·Shumei Song, Soichiro Honjo, Jiankang Jin, Sam S. Chang, Ailing W. Scott, Qiongrong Chen, Neda Kalhor, Arlene M. Correa, Wayne L. Hofstetter, Constance T. Albarracin, Tsung‐Teh Wu, Randy L. Johnson, Mien‐Chie Hung, Jaffer A. Ajani	2015	200
11	Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties Cancer Research ·Shumei Song, Jaffer A. Ajani, Soichiro Honjo, Dipen M. Maru, Qiongrong Chen, Ailing W. Scott, Todd R. Heallen, Lianchun Xiao, Wayne L. Hofstetter, Brian Weston, Jeffrey H. Lee, Roopma Wadhwa, Kazuki Sudo, John R. Stroehlein, James F. Martin, Mien‐Chie Hung, Randy L. Johnson	2014	211
12	Loss of TGF-β Adaptor β2SP Activates Notch Signaling and SOX9 Expression in Esophageal Adenocarcinoma Cancer Research ·Shumei Song, Dipen M. Maru, Jaffer A. Ajani, Chia‐Hsin Chan, Soichiro Honjo, Hui‐Kuan Lin, Arlene M. Correa, Wayne L. Hofstetter, Marta Davila, John Stroehlein, Lopa Mishra	2013	57
13	Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection Journal of Clinical Oncology ·Stephen R. Smalley, Jacqueline Benedetti, Daniel G. Haller, Scott A. Hundahl, Norman Estes, Jaffer A. Ajani, Leonard L. Gunderson, Bryan Goldman, James A. Martenson, J. Milburn Jessup, Grant N. Stemmermann, Charles D. Blanke, John S. Macdonald Hit paper breakdown →	2012	591
14	Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models Molecular Cancer Therapeutics ·Jae‐Ho Cheong, Eun Sung Park, Jiyong Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Joonsuk Bae, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Murali K. Ravoori, Vikas Kundra, Jaffer A. Ajani, Ju‐Seog Lee, Waun Ki Hong, Gordon B. Mills	2011	205
15	Gene Expression Signature–Based Prognostic Risk Score in Gastric Cancer Clinical Cancer Research ·Y. Choi, Jae Yun Lim, Jae‐Ho Cheong, Yun‐Yong Park, Lei Chu, Soo Mi Kim, Sang-Bae Kim, Hoguen Kim, Soon Won Hong, Young Nyun Park, Sung Hoon Noh, Eun Sung Park, In‐Sun Chu, Waun Ki Hong, Jaffer A. Ajani, Ju‐Seog Lee	2011	269
16	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial Journal of Clinical Oncology ·Jaffer A. Ajani, W. Rodriguez, G. Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, В. А. Горбунова, Ihor Vynnychenko, August Garin, István Láng, S. Falcon Hit paper breakdown →	2010	425
17	Genome-Wide Catalogue of Chromosomal Aberrations in Barrett's Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis Cancer Prevention Research ·Jian Gu, Jaffer A. Ajani, Ernest T. Hawk, Yuanqing Ye, Jeffrey H. Lee, Manoop S. Bhutani, Wayne L. Hofstetter, Stephen G. Swisher, Kenneth K. Wang, Xifeng Wu	2010	67
18	Constitutive Short Telomere Length of Chromosome 17p and 12q but not 11q and 2p Is Associated with an Increased Risk for Esophageal Cancer Cancer Prevention Research ·Jinliang Xing, Jaffer A. Ajani, Meng Chen, Julie Izzo, Jie Lin, Zhi‐Nan Chen, Jian Gu, Xifeng Wu	2009	63
19	MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma Clinical Cancer Research ·Hushan Yang, Jian Gu, Kenneth K. Wang, Wei Zhang, Jinliang Xing, Zhi‐Nan Chen, Jaffer A. Ajani, Xifeng Wu	2009	109
20	Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma Cancer Research ·Chia-Jui Yen, Julie Izzo, Dung‐Fang Lee, Sushovan Guha, Yongkun Wei, Tsung‐Teh Wu, Chun‐Te Chen, Hsu-Ping Kuo, Jung-Mao Hsu, Hui-Lung Sun, Chao‐Kai Chou, Navtej Buttar, Kenneth K. Wang, Peng Huang, Jaffer A. Ajani, Mien‐Chie Hung	2008	49

About Jaffer A. Ajani

Jaffer A. Ajani is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Cancer Research, having authored 939 papers that have together received 45.2k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (544 papers), Esophageal Cancer Research and Treatment (324 papers), Colorectal Cancer Treatments and Studies (141 papers), Gastrointestinal Tumor Research and Treatment (140 papers), Esophageal and GI Pathology (136 papers), Metastasis and carcinoma case studies (124 papers), Pancreatic and Hepatic Oncology Research (85 papers) and Colorectal and Anal Carcinomas (77 papers). The work is most often cited by research in Gastroenterology (6.7k citations), Pulmonary and Respiratory Medicine (26.9k citations), Oncology (16.8k citations), Surgery (21.2k citations) and Cancer Research (4.6k citations). Jaffer A. Ajani has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Stephen G. Swisher, Leonard L. Gunderson, Wayne L. Hofstetter, Shumei Song, Daniel G. Haller, James C. Yao, Norman Estes, Jack A. Roth, Arlene M. Correa and Eric Van Cutsem. Their work appears in journals such as Journal of Clinical Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology and Annals of Surgical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact